Article Information
History
- June 20, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- William Jordan, DVM, PhD, DACVP1,
- Richard Siegel, PhD2,
- Rajendra Kumar, PhD3 and
- Jonathan Javitt, M.D., M.P.H.2,*
- 1Vet Path Services, Inc, 6450 Castle Drive, Mason, Ohio
- 2NeuroRx, 1201 N. Market Street, Suite 200, Wilmington, DE 19801
- 3WuXi Apptec, Inc., Free Trade Zone, Pudong, China
- ↵*Corresponding author: Jonathan C. Javitt, MD, MPH, Chief Scientist, NeuroRx, Inc. 1201 N Market Street, Wilmington, DE 19801, Tel: 202-340-1352 Email: jjavitt{at}nrxpharma.com
Author contributions RS and JJ conceived of the study and oversaw all regulatory matters. RK directed formulation of investigational product, dosing of experimental subjects, and measurement of toxokinetics, WJ directed preparation of histological specimens and their interpretation, BG provided scientific writing.
Posted June 20, 2022.
NRX-101, A RAPID-ACTING ANTI-DEPRESSANT, DOES NOT CAUSE NEUROTOXICITY FOLLOWING KETAMINE ADMINISTRATION IN PRECLINICAL MODELS
